Bristol-Myers's Baraclude Found Effective in Hepatitis Study
Posted on: Monday, 28 April 2008, 09:00 CDT
Bristol-Myers Squibb has announced positive data from the Early study, in which treatment of antiviral-naive adult chronic hepatitis B patients with Baraclude resulted in greater long-term viral load reduction than adefovir at 96 weeks, consistent with earlier 12-week results.
The Early study is an open-label, randomized, viral kinetics study of 69 antiviral-naive chronic hepatitis B e-antigen (HBeAg) positive patients, comparing the antiviral activity of Baraclude and adefovir. All patients in this study had a high viral load at study entry.
Of the 49 patients who remained in the study at 96 weeks, 79% (n=23/29) of Baraclude-treated patients and 50% (n=10/20) of adefovir-treated patients achieved undetectable viral load. The mean reduction in viral load from baseline in patients treated with Baraclude was -7.82 log(10) copies/mL and was -5.96 log(10) copies/mL in patients treated with adefovir at week 96.
The safety profile was comparable between the treatment groups through 96 weeks. Three percent of patients receiving Baraclude (entecavir) (n=1) and 12% of patients receiving adefovir (n=5) experienced a serious adverse event. By week 96, 22 of the 69 enrolled patients had discontinued the study. Of these, two patients receiving adefovir discontinued due to investigator-determined lack of treatment efficacy between the beginning of year two dosing and the 96-week analysis.
Source: Datamonitor
Related Articles
- Physicians Have Less Respect For Obese Patients, Study Suggests
- Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology From Varian Medical Systems
- Radiation Oncology Associates of New York Becomes First in New York to Offer Patients a New, Faster Radiotherapy for Treating Cancer
- Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
- Studies: TB Can Be Treated in Few Months
- Vicriviroc Demonstrates Potent Viral Suppression Through 48 Weeks of Therapy in ACTG Phase II Study in Treatment-Experienced HIV Patients
- Oculus' Dermacyn(R) Wound Care Subject of 33-Patient Study Published in International Journal of Lower Extremity Wounds
- Hypothermia May Benefit Cardiac Patients: Study
- China Begins Clinical Studies on Anti-Viral Drug to Combat Bird Flu
- Prayer Doesn't Help Heart Surgery Patients: Study
 |
 |
User Comments (0)
RSS Feeds